Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01356940 · ClinicalTrials.gov registry record · Phase 4
A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis
A Phase 4 study, sponsored by Brown, Theodore R., M.D., MPH.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT01356940: Completed Phase 4 study, sponsored by Brown, Theodore R., M.D., MPH.
NCT01356940 is a Phase 4 study that has completed, run by Brown, Theodore R., M.D., MPH. The registered enrollment target is 43 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01356940, a Phase 4 study, has completed, sponsored by Brown, Theodore R., M.D., MPH.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
A randomized placebo controlled double-blind cross-over trial of Dalfampridine ER for effect on ambulatory activity in people with multiple sclerosis
Primary Outcome
peak activity index is a measure of the 30 fastest minutes of walking over a 24 hour period, averaged over one week of accelerometer wear. Measurement is change from baseline to 4 weeks on intervention
Interventions
- DRUG placebo
- DRUG dalfampridine ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
What the finished NCT01356940 record still lists
NCT01356940 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01356940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01356940 about?
NCT01356940 is a clinical study titled "A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis". A randomized placebo controlled double-blind cross-over trial of Dalfampridine ER for effect on ambulatory activity in people with multiple sclerosis
What is the current status of trial NCT01356940?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2010-11. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01356940?
The interventions under investigation include: placebo (DRUG), dalfampridine ER (DRUG).
Who is sponsoring clinical trial NCT01356940?
This trial is sponsored by Brown, Theodore R., M.D., MPH, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01356940's enrollment target sits among peer trials
43 1371st of 2000 higher than 621 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia